Stock Track | BIOCYTOGEN-B Soars 5.19% Intraday on Hong Kong Stock Connect Inclusion and Strong Earnings Growth

Stock Track2025-12-29

BIOCYTOGEN-B (02315) saw its stock price surge 5.19% during Monday's intraday trading session, driven by its recent inclusion in the Hong Kong Stock Connect list and robust earnings performance.

The Shanghai and Shenzhen Stock Exchanges announced BIOCYTOGEN-B's addition to the Hong Kong Stock Connect list, effective from December 24, 2025. This inclusion is expected to broaden the company's investor base, enhance liquidity, and alleviate valuation discounts caused by insufficient liquidity. Historically, such inclusions have acted as catalysts for value reassessment of listed companies.

BIOCYTOGEN-B's strong financial results further bolstered investor confidence. For the first three quarters of 2025, the company reported a 59.5% year-on-year revenue increase to 941 million yuan and a net profit of 114 million yuan, marking a significant turnaround from the previous year's loss. The company's global expansion and partnerships with top pharmaceutical firms also underscore its growth potential.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1189874420?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-29 09:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1189874420","market":"nz","top_or_hot":-1,"title":"Stock Track | BIOCYTOGEN-B Soars 5.19% Intraday on Hong Kong Stock Connect Inclusion and Strong Earnings Growth","media":"Stock Track","content":"<p>BIOCYTOGEN-B (02315) saw its stock price surge 5.19% during Monday's intraday trading session, driven by its recent inclusion in the Hong Kong Stock Connect list and robust earnings performance.</p><p>The Shanghai and Shenzhen Stock Exchanges announced BIOCYTOGEN-B's addition to the Hong Kong Stock Connect list, effective from December 24, 2025. This inclusion is expected to broaden the company's investor base, enhance liquidity, and alleviate valuation discounts caused by insufficient liquidity. Historically, such inclusions have acted as catalysts for value reassessment of listed companies.</p><p>BIOCYTOGEN-B's strong financial results further bolstered investor confidence. For the first three quarters of 2025, the company reported a 59.5% year-on-year revenue increase to 941 million yuan and a net profit of 114 million yuan, marking a significant turnaround from the previous year's loss. The company's global expansion and partnerships with top pharmaceutical firms also underscore its growth potential.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | BIOCYTOGEN-B Soars 5.19% Intraday on Hong Kong Stock Connect Inclusion and Strong Earnings Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | BIOCYTOGEN-B Soars 5.19% Intraday on Hong Kong Stock Connect Inclusion and Strong Earnings Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-12-29 09:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BIOCYTOGEN-B (02315) saw its stock price surge 5.19% during Monday's intraday trading session, driven by its recent inclusion in the Hong Kong Stock Connect list and robust earnings performance.</p><p>The Shanghai and Shenzhen Stock Exchanges announced BIOCYTOGEN-B's addition to the Hong Kong Stock Connect list, effective from December 24, 2025. This inclusion is expected to broaden the company's investor base, enhance liquidity, and alleviate valuation discounts caused by insufficient liquidity. Historically, such inclusions have acted as catalysts for value reassessment of listed companies.</p><p>BIOCYTOGEN-B's strong financial results further bolstered investor confidence. For the first three quarters of 2025, the company reported a 59.5% year-on-year revenue increase to 941 million yuan and a net profit of 114 million yuan, marking a significant turnaround from the previous year's loss. The company's global expansion and partnerships with top pharmaceutical firms also underscore its growth potential.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02315","symbol_name":"百奥赛图-B","start_time":0,"source_url":"","article_id":"1189874420","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1189874420","pubTimestamp":1766972210,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"BIOCYTOGEN-B (02315) saw its stock price surge 5.19% during Monday's intraday trading session, driven by its recent inclusion in the Hong Kong Stock Connect list and robust earnings performance.The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02315":"百奥赛图-B"},"translate_title":"个股赛道|百奥赛图-B盘中大涨5.19%港股通纳入盈利强劲增长","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02315":1},"content_text":"BIOCYTOGEN-B (02315) saw its stock price surge 5.19% during Monday's intraday trading session, driven by its recent inclusion in the Hong Kong Stock Connect list and robust earnings performance.The Shanghai and Shenzhen Stock Exchanges announced BIOCYTOGEN-B's addition to the Hong Kong Stock Connect list, effective from December 24, 2025. This inclusion is expected to broaden the company's investor base, enhance liquidity, and alleviate valuation discounts caused by insufficient liquidity. Historically, such inclusions have acted as catalysts for value reassessment of listed companies.BIOCYTOGEN-B's strong financial results further bolstered investor confidence. For the first three quarters of 2025, the company reported a 59.5% year-on-year revenue increase to 941 million yuan and a net profit of 114 million yuan, marking a significant turnaround from the previous year's loss. The company's global expansion and partnerships with top pharmaceutical firms also underscore its growth potential.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1189874420","isCrawlerRequest":true}